Mobile website
Archive > Volume 22 Issue 6 > 2015,22(6):785-789. DOI:10.3872/j.issn.1007-385X.2015.06.018 Prev Next
Clinical Research
Clinical study of combined immunotherapy with tumor antigen-pulsed dendritic cells and cytokine-induced killer cells for relapsed multiple myeloma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the clinical efficacy and safety of combined immunotherapy with dendritic cells (DCs) and cytokine-induced killer (CIK) cells in the treatment of relapsed multiple myeloma(MM). Methods: Bone marrow myeloma cells and peripheral blood mononuclear cells were collected from 22 cases of relapsed MM. The autologous DCs and CIK cells were amplified in vitro and used for reinfusion treatment. The clinical responses and immune parameters before and after the treatment were compared. Results: Among the 22 patients, 2 had CR in response to the combined therapy, 5 had nCR, 7 had PR, 3 had MR, and 5 had PD. Thus, the overall response rate (CR+nCR+PR) was 63.64% (14/22). After the treatment, the percentages of T cells subsets in peripheral blood did not change significantly (P>005), whereas the percentage of NK cells increased significantly (\[22.26±9.67\]% vs \[12.61±8.78\]%, P<001). Furthermore, the blood levels of LDH (\[166±41\]% vs \[112±21\]%) and β2-MG (\[5.11±2.33\]% vs \[265±1.61\]%) were significantly improved following the immunotherapy (P<0.01). Conclusion: The combined therapy with DC and CIK cells are safe and effective for relapsed MM. The treatment should be further tried in more patients with multiple myeloma and perhaps patients with B cell malignancies.
Keywords:
Project Supported:
Project supported by the Six Top Talents Foundation of Jiangsu Province（No. 2010-WS-012），and the Medical Talents Foundation of Jiangsu Province（No.2014-333-063）
Clc Number:
